Satigrel

An antiplatelet medication used in the prevention of thrombotic cardiovascular events.

Satigrel is an antiplatelet medication primarily used in the prevention of thrombotic cardiovascular events such as myocardial infarction and stroke. It functions by inhibiting platelet aggregation, thereby reducing the risk of clot formation in the arteries.

Mechanism of Action

Satigrel works by selectively inhibiting the P2Y12 receptor, a key receptor on the surface of platelets that is involved in the activation and aggregation of platelets. By blocking this receptor, Satigrel prevents the binding of adenosine diphosphate (ADP), a crucial step in the platelet activation process. This inhibition reduces the ability of platelets to clump together, thus decreasing the likelihood of thrombus formation.

Pharmacokinetics

Satigrel is administered orally and has a high bioavailability. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system. The drug has a half-life of approximately 7 hours, and its metabolites are excreted mainly through the kidneys.

Clinical Uses

Satigrel is indicated for the prevention of:

• Acute coronary syndrome (ACS)
• Myocardial infarction
• Ischemic stroke
• Peripheral arterial disease

Adverse Effects

Common side effects of Satigrel include:

• Bleeding
• Gastrointestinal upset
• Headache

Serious adverse effects may include:

• Severe bleeding
• Thrombocytopenia

Contraindications

Satigrel is contraindicated in patients with:

• Active pathological bleeding
• Hypersensitivity to the drug or its components

Drug Interactions

Satigrel may interact with other medications that affect hemostasis, such as:

• Warfarin
• Nonsteroidal anti-inflammatory drugs (NSAIDs)

Also see

• Antiplatelet drug
• Thrombosis
• Cardiovascular disease
• Clopidogrel

References

Template:Antiplatelet drugs